Find a Clinical Trial

In conjunction with our mission to advance the science and practice of clinical psychopharmacology through education and research, ASCP is committed to the support and promotion of clinical trials. We encourage practitioners and patients to investigate and participate in clinical trials when available and appropriate. To list a clinical trial on the website, please submit information to info@ascpp.org.

 

Clinical Trial from UC San Diego, San Diego, California

  • For more information click here.  NCT04953832, Anxiety disorders are highly prevalent and costly to the individual and society. Exposure-based cognitive behavioral therapy (CBT) is the gold-standard intervention for anxiety disorders, although this approach does not fully reduce symptoms for all individuals. Therefore there is a need for innovative intervention approaches. One approach to augment and improve existing therapies would be to enhance the neurocognitive basis of fear extinction processes, which are the model on which treatments are based. Enhancing these processes may be possible through computerized cognitive training techniques which target executive functioning, the cognitive processes that help people manage complex cognitive activities. The proposed project is a proof-of-concept pilot study investigating the potential for training of executive functioning to improve anxiety-related outcomes. Individuals with elevated levels of social anxiety will be randomized to single-session COGnitive Enhancement Training (COGENT) or sham training program (ST). All participants will complete a single speech session where they present three 7-minute impromptu speeches and rate their anxiety at specific intervals. Participants will then complete the COGENT paradigm and affective processing task while undergoing fMRI.

Clinical Trial from Medical University of South Carolina, Charleston, South Carolina

  • For more information click here.  NCT04951193, The purpose of this study is to evaluate a mobile application (app) called “Goal2QuitVaping” to help adolescents quit vaping nicotine. Goal2QuitVaping was developed by our research team to assist with quitting vaping. Participants will be randomly assigned to either download the mobile app, “Goal2QuitVaping”, or not. If provided with Goal2QuitVaping, participants will be asked to use the app regularly, at least once per day, throughout the study duration. Participants will be asked to complete electronic questionnaire measures throughout the study period. Participation in this study will take about 4 weeks.

Clinical Trial from Laureate Institute for Brain Research, Tulsa, Oklahoma 

  • For more information click here.  NCT04941066, Neuroimaging MRI techniques for measuring brain structure, tissue composition, and Blood Oxygenation Level Dependent functional Magnetic Resonance imaging (BOLD fMRI) will be used to measure task-dependent and task-independent brain hemodynamic and electrophysiological changes in human subjects with major depressive disorders (MDD).

    After being informed about the study and potential risks, all participants giving written informed consent will undergo one session of the cognitive process-based fMRI neurofeedback (CNF) targeting the rumination-related brain functional connectivity, and a one-week follow-up. Participants will be randomized in a double-blind manner (participant and investigator) in a 1:1 ratio to Active (receiving feedback from their own brain activity) or Sham (receiving artificially generated feedback).

Clinical Trial from WVU Medicine, Morgantown, West Virginia

  • For more information click here.  NCT04876066, Studies have shown that ketamine is very effective and has a quick onset in treatment of depression. Most of these studies used intravenous ketamine in an inpatient setting and there are no large trials examining its use in Post Stroke Depression (PSD). There have been only few studies that have used other routes of administration (i.e., oral, transmucosal, intranasal, intramuscular) of ketamine which provided symptom relief for depression. The purpose of this study is to assess the effectiveness and safety of use of transmucosal ketamine in treatment of PSD. We hypothesize that fast acting antidepressant effects can be achieved with tolerable side effects for translation into the general post-stroke population. To test our hypothesis, the specific aim is to: (1) demonstrate that transmucosal administration of ketamine is feasible within the post-stroke depression population and has tolerable side effects. Exploratory aims will include assessment if ketamine also produces fast acting antidepressant effects.

Clinical Trial from University of Rutgers, Piscataway, New Jersey

  • For more information click here.  NCT04926090,This study has three specific aims: Aim 1: Identify mental health needs of autistic students to inform supports. Focus groups engaging key stakeholders will be used to understand the mental health needs of autistic college students and inform adaptation of two individualized mental health supports: 1) the ESP intervention and 2) protocols for monitoring mood and psychological distress. Aim 2: Develop resources to inform and guide mental health care of autistic students. Focus group information will inform 1) adaptation of clinician (ESP-C) and self-guided (ESP-S) emotional support plans and monitoring protocols and 2) develop a “College Student Mental Health Guide” to aide autistic college students, their families and mental health professionals in proactive planning for mental health supports during PSE. Aim 3: Assess the feasibility, acceptability and initial efficacy of the ESP-C and ESP-S. The study will yield preliminary data to apply for additional funding to conduct a large-scale trial to validate these methods to monitor and support mental health of autistic adults. Information gathered from the study will also be used to inform development of a mental health guide for autistic students.

Clinical Trial from Trama and Stress Studies Center, Houston, Texas

  • For more information click here. NCT04909216, The overarching goal of this study is to demonstrate the efficacy, feasibility, and acceptability of Mindful Attention Training (MAT), a novel mindfulness-based intervention that is specifically developed for firefighters. This project is designed to improve the health of firefighters, an integral, essential component of our national and international communities. Moreover, the study aims to promote health service psychologists by enhancing our contributions to the mental healthcare of firefighters, an understudied and underserved segment of the population by virtue of their service to our communities. This study therefore has significant potential to identify, develop, and promote an effective model of quality, evidence-based mental health promotion and illness prevention by integrating health service psychology into the fire service.

Clinical Trial from University of California San Francisco, San Francisco, California

  • For more information click here.  NCT04872179, This is an international prospective registry of patients with Alpha thalassemia to understand the natural history of the disease and the outcomes of fetal therapies, with the overall goal of improving the prenatal management of patients with Alpha thalassemia.

Clinical Trial from Johns Hopkins Bayview Medical Center, Baltimore, Maryland

  • For more information click here.  NCT04872439, Gastrointestinal motility disorders represent a heterogeneous group of neuromuscular diseases of the enteric nervous systems. While autoimmune neuromuscular diseases of the central nervous system (CNS) are well described, the role of autoimmunity in enteric nervous system (ENS) has been less studied. Approximately 10% of patients with unexplained gastrointestinal dysmotility diseases have positive serum autoantibodies to peripheral nervous system proteins, suggesting an autoimmune mechanism targeting the enteric nervous system. Our aim is to identify novel anti neuronal antibodies that contribute to autoimmune gastrointestinal motility disorders by analyzing the serum of patients with abnormal gastrointestinal motility.

Clinical Trial from University of Wisconsin, Madison, Wisconsin 

  • For more information click here.  NCT04871074, The overarching goal of this project is to use [C-11]UCB-J to obtain spatial information on neuronal synapse abundance and inform Alzheimer’s disease (AD) progression. The investigators propose to collect longitudinal amyloid, tau, and Synaptic vesicle glycoprotein 2A (SV2A) positron emission tomography (PET) in participants in the Wisconsin Alzheimer’s Disease Research Center (ADRC) and Wisconsin Registry for Alzheimer’s Prevention (WRAP) across the clinical stages of AD, including cognitively unimpaired biomarker negative, unimpaired biomarker positive, mild cognitive impairment (MCI), and dementia due to AD.

Clinical Trial from University of Michigan, Ann Arbor, Michigan

  • For more information click here.  NCT04821830, The most effective treatment for PD is the drug levo-dopa, which partially replaces brain dopamine. Despite decades of successful use, how levo-dopa improves speed of movement in PD is not understood. This observational study recruits participants who have been prescribed levo-dopa by their treating physicians. Before their first dose, immediately after their first dose and later, when their dose has been stabilized, they will engage with the research team to participate in a few simple experiments to measure speed, grip strength, tremor, and stability (on and off of treatment). The purpose of these experiments is to understand how levo-dopa treatment in Parkinson disease enhances movement speed. An important but not understood component of levo-dopa action, the Long Duration Response (LDR), lasts for days to weeks. A basic function of dopamine signaling in the brain is modulation of motivation – the coupling between effort and action values. These experiments will determine if the LDR is associated with relative normalization of motivation function in the brain. The motivation behavior of recently diagnosed PD participants will be examined before and after treatment with levo-dopa to determine if the magnitude of the LDR is correlated with improvements in motivation behavior.

Clinical Trial from OtolithLabs, Washington, District of Columbia

  • For more information click here.  NCT04787653, This proposed study is a blinded study in which the participant will wear the OtoBand when their tinnitus is present to determine if the OtoBand reduces the perceived loudness of their tinnitus. The Study will be placebo controlled with each participant using an effective device for half of the enrollment period and a placebo device for half of the enrollment period. The order of placebo and effective usage will be randomized, and the researchers will be blinded to which device a participant is using. Study participants will be instructed in an online telehealth conference on how to operate the OtoBand and how to wear the OtoBand. Participants will be enrolled for approximately 30 days from Informed Consent to Wrap-up call.

Clinical Trial from H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida

  • For more information click here.  NCT04741997, The purpose of this study is to assess rate of disease relapse and hazard rate of disease relapse after neoadjuvant therapy based on the statuses of pathologic complete response or non-pathologic complete response, and postoperative adjuvant therapy.

Clinical Trial from National Institutes of Health Clinical Center, Bethesda, Maryland

  • For more information click here.  NCT04698382, This study seeks to determine the the impact of COVID-19 on the incidence, characteristics, management and outcome of patients admitted to U.S. hospitals with non-COVID-19 related sepsis.

Clinical Trial from YSOPIA Bioscience, Lincoln, Nebraska

  • For more information click here.  NCT04663139, Xla1 Christensenella minuta, phase I, randomized, placebo-controlled double-blind protocol, evaluating safety, tolerability and impact on the gut microbiota in healthy volunteers, overweight and obese adults. This study is designed as a FIH, Phase I, daily oral single dose, clinical trial evaluating safety, tolerability and the impact on the gut microbiota following introduction of Xla1 performed in 2 parts: Part 1: An open phase in normal weight healthy volunteers (HV) receiving all Xla1. Part 2: A randomized, parallel, double-blind, placebo-controlled phase in overweight or obese (stage 1) adult patients receiving either Xla1 or placebo.

Clinical Trial from Parexel, Glendale, California

  • For more information click here.  NCT04620109, A Phase 1 randomized, double-blinded, placebo-controlled, single-dose escalation (SDE) and repeat dose escalation (RDE) study to evaluate safety and tolerability, and PK of KDR2-2 in healthy volunteers. The planned single dose levels are 0.03, 0.06, 0.12, and 0.24 mg/eye, and repeat dose levels are 0.06, 0.12, and 0.24 mg/eye, QID, × 6 days (one dose in the morning on Day 7). Subjects are randomized to KDR2-2 or placebo dosing (6:2 for SDE, or 8:2 for RDE) in each cohort of relative dosing levels.

Clinical Trial from Nemours Children’s Clinic, Wilmington, Delaware

  • For more information click here.  NCT04577417, Attention-deficit/hyperactivity disorder (ADHD) is the most common neurodevelopmental disorder in children. Besides core ADHD symptoms (inattentiveness, hyperactivity, impulsivity), ADHD also affects the ability to perceive and process sounds. Both hypersensitivity and hyposensitivity to loud sounds are common symptoms in ADHD patients. With stimulant medication, individuals with ADHD become more tolerant of loud noise than when they were non-medicated. It remains unknown exactly how stimulant medication alters the loudness perception. The proposed study will use the acoustic reflex to objectively measure auditory sensitivity to loud sounds. The aims of this study are to evaluate auditory sensitivity in patients with ADHD using acoustic reflex thresholds (ART) and to examine the effects of ADHD stimulant medication on ART. Eligible participants will participate in two sessions (off-med and on-med conditions) conducted on the same day. ADHD patients will be asked to come to the laboratory before taking their ADHD medication. The investigators will repeat three tests before and after taking stimulant medication. The investigators will also conduct screening tests during and between the first and second sessions. The investigators will compare a difference between the two independent groups (ADHD vs. Control) and compare a within subject difference between medication conditions (on-med vs. off-med).

Clinical Trial from Dr. Daniel P Morin, MD MPH FHRS, Ochsner Health System

  • For more information click here.  NCT04539158,”Dual-DCCV” is a technique in which four pads are used to deliver two simultaneous shocks of 200J, totaling 400J. Guidelines published by the American Heart Association/American College of Cardiology/Heart Rhythm Society and the European Society of Cardiology provide only general guidance regarding the appropriate technique and energy selection in patients undergoing cardioversion, with no specific recommendations pertaining to dual-DCCV or obese patients. This study aims to assess the safety and efficacy of dual-DCCV as an initial treatment strategy, compared to standard single-DCCV, in the obese population.

Clinical Trial from Ochsner Medical Center, New Orleans, Louisiana

  • NCT04539158, Currently, the usual initial strategy for direct current cardioversion (DCCV) typically involves delivering 200J of electricity between two pads placed in the anterior and posterior positions (i.e., one on the chest and one on the back). However, this technique may be less likely to result in successful cardioversion in obese patients (BMI ≥30 kg/m2). Failure to achieve sinus rhythm then necessitates additional shocks, which still may ultimately fail to terminate the patient’s atrial fibrillation, thereby increasing the likelihood of adverse events from multiple cardioversion attempts “Dual-DCCV” is a technique in which four pads are used to deliver two simultaneous shocks of 200J, totaling 400J. Guidelines published by the American Heart Association/American College of Cardiology/Heart Rhythm Society and the European Society of Cardiology provide only general guidance regarding the appropriate technique and energy selection in patients undergoing cardioversion, with no specific recommendations pertaining to dual-DCCV or obese patients. This study aims to assess the safety and efficacy of dual-DCCV as an initial treatment strategy, compared to standard single-DCCV, in the obese population.

Clinical Trial from Vanderbilt University Medical Center, Nashville, Tennessee

  • NCT02332291, This challenge is in part due to age-related vascular changes that are common in LLD. Successful antidepressant treatment involve changes across affective, cognitive, and default mode networks. We hypothesize that in LLD, vascular disease adversely affects response to antidepressants by disrupting connectivity of these networks. The primary goal of this project is to characterize how focal vascular damage affects regional connectivity and response to antidepressants. Based on past work and pilot data, we a priori focus on the cingulum bundle and uncinate fasciculus. These key fiber bundles connect frontal, temporal, and cingulate regions involved in cognition and affective responses. Our central hypothesis is that ischemic damage to the cingulum bundle and uncinate fasciculus contributes to structural and functional connectivity deficits of those tracts. This results in a disconnection effect that alters the function of connected regions. In turn, this increases the risk of a poor response to antidepressants.

Clinical Trial from University of Louisville, Louisville, Kentucky

  • NCT03786614, The purpose of this study is to compare the effects on depressive symptoms of subjects who discontinue serotonergic antidepressants (a certain type of antidepressant, such as Prozac, that works on serotonin receptors in the brain) with the effects on depressive symptoms of subjects who continue to take serotonergic antidepressants. During this study, subjects will also be presented with the opportunity to undergo genetic testing for the serotonin gene transporter which has a short or long form. This is being done because it has been demonstrated that genetic testing improves outcome while treating treatment-resistant depression.

Clinical Trial from Massachusetts General Hospital, Boston, Massachusetts

  • NCT03538431, This study will examine the effects of treatment with the anti-anxiety medicine buspirone on driving performance (eye tracking) in individuals with high-functioning autism spectrum disorder (HF-ASD). 

Clinical Trial from National Institutes of Health Clinical Center, 9000 Rockville Pike, Maryland

  • NCT02153944, The overall aim of this protocol is to examine the effect of pharmacological manipulations of affective and cognitive processes on anxiety and task performance. Ultimately, the goal is 1) to provide insight into the relative influence of cognitive and affective states on anxiety, 2) generate theoretical models that can be applied to a better understanding of the interaction between cognition and emotion, 3) develop a better screening approach to candidate anxiolytics, and 4) help formulate novel therapeutic interventions for clinical anxiety.

Clinical Trial from Harmonex Neuroscience Research, Inc., Alabama and Woodland International Research Group Inc., Arkansas

  • NCT02075047, The purpose of this study is to determine if ziprasidone is safe and effective for the treatment of children and adolescents (ages 10-17) with bipolar I disorder (manic or mixed).

Clinical Trial from Massachusetts General Hospital, Boston

  • NCT04189575, This study will assess the efficacy of the text messaging (SMS-based) disease management intervention to improve adherence to stimulants in adults with Attention Deficit/Hyperactivity Disorder (ADHD) within the Partners primary and psychiatry care settings. Participants in the study will receive customized text messages twice a day, every day, for a duration of 9 months. The text messages will include reminders to adhere to the individualized medication regimen, reminders to call their clinician for a prescription refill followed by reminders to pick up medication from the pharmacy, and educational reminders about ADHD and its treatment

Clinical Trial from Rutgers, The State University of New Jersey

  • NCT04047355, This study will pilot the safety and efficacy of high dose propranolol. The investigators will randomly assign participants to either propranolol or to placebo later crossing each participant over to the other group. As propranolol can cause changes in blood pressure and heart function, each participant will complete initial comprehensive testing to monitor cardiac safety throughout the study. The investigators will be utilizing telemedicine and computer based telemetry to minimize the burden of office visits on the individual and family.

Clinical Trial from Massachusetts General Hospital, Boston

  • NCT03553875, This study is a 12-week randomized-controlled trial of memantine hydrochloride (Namenda) for the treatment of social impairment in youth with Non-Verbal Learning Disorder, High-Functioning Autism Spectrum Disorder, and related conditions. Eligible participants will be males and females ages 8-18.

Clinical Trial from California State University, San Marcos

  •  NCT03934723, The aim of the proposed study is to compare the efficacy of 6 weeks of exercise training to reduce abdominal fat in healthy overweight/obese adults either taking or not taking antidepressant medication. Twenty-four inactive overweight/obese, but otherwise healthy, adults will complete 6 weeks of an exercise training intervention consisting of three days of aerobic exercise training per week. Participants will either not be taking antidepressant medication or will have been on their medication for at least 1 year. The primary outcome will be abdominal fat determined by waist circumference and dual x-ray absorptiometry, which is considered one of the optimal methods for assessment of abdominal fat.

Clinical Trial from Brasilia University Hospital

  • NCT03075241, Sleep disorders (SD) affects 35 to 50 percent of patients with AD. These disorders often make caring for patients at home very difficult. Zolpidem and Zoplicone are prescribed drugs for sleep disorder in AD patients.

Clinical Trial from Christoph U. Correll and Northwell University  

  • NCT01383915, The purpose of the study is to characterize the at-risk phases preceding a first episode of bipolar disorder and of schizophrenia, and to identify clinical and biological predictors of the disease development. Hypothesis a: Over 6-24 months, 25% of at-risk youth will develop the full manifestations of Bipolar Disorder (BPD) or schizophrenia. Hypothesis b: The symptoms utilized for characterizing the at-risk phase of BPD will differentiate between individuals developing BPD and schizophrenia

Clinical Trial from Yale University 

  • NCT03539900 Binge-eating disorder (BED), the most prevalent formal eating disorder, is associated strongly with obesity and bio-psychosocial impairment. Improved treatments for patients with BED are needed that can produce sustained clinical outcomes. This study aims to test the efficacy of Naltrexone/Bupropion (NB; FDA-approved anti-obesity combination medication) for the treatment of BED in patients with and without obesity. The RCT will provide new findings regarding the efficacy of NB medication for reducing binge-eating episodes among patients with BED, for reducing weight among patients with BED and obesity, and whether patients with and without obesity derive differential benefit from NB.

Clinical Trial from the University of North Carolina, Chapel Hill

  •  NCT03287778 Randomized Controlled Trial of Pyridoxine for Tardive Dyskinesia: This study will test the efficacy of pyridoxine (also known as vitamin B6) for TD. This will be an 8 week double-blind, placebo-controlled, randomized trial measuring the effect of pyridoxine 400 mg/day on the severity of involuntary muscle movements in people who meet Schooler-Kane criteria for TD..

A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia 

  •  NCT03627195 A study to determine the maximum tolerated dose of an investigational drug in subjects with schizophrenia. This is a single-center, randomized, double-blind, placebo-controlled, inpatient, single ascending dose (SAD) study designed to evaluate the safety, tolerability, and PK of lurasidone injectable suspension in subjects with schizophrenia

Ion Channel Genetic Biomarkers: Diagnostic Capabilities in the Assessment of Bipolar Disorder 

  •  NCT03572426 ,Genotype 164 adults to evaluate six selected single nucleotide polymorphisms (SNPs) (rs1006737, rs10994336, rs10994133, rs2238071, rs1051375, rs1024582) for use as a genetic biomarker to differentiate between bipolar depression and unipolar depression.

Neurofunctional Predictors of Escitalopram Treatment Response in Adolescents With Anxiety (FiESTAA) 

  • NCT02818751 , Neurofunctional Predictors of Escitalopram Treatment Response in Adolescents with Anxiety. To determine the effects of escitalopram on functional activation patterns during a Continuous Performance Task with Emotional and Neutral Distracters, the CPT-END.

Clinical Trials from Northwestern University Psychiatric Clinical Research Program 

  • NCT02466685, The goals of this study are to evaluate the efficacy of JNJ-18038683 in an 8 week trial to ameliorate the cognitive deficit and reduce residual depressive symptoms in 60 stable bipolar outpatients receiving treatment for depression

 Clinical Trials from Otsuka Pharmaceutical Development & Commercialization, Inc.

  • NCT03287869 A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Bipolar I Disorder
 

Clinical Trials from Medical University of South Carolina

  • NCT03334721 Gabapentin for Bipolar & Cannabis Use Disorders
 

Clinical Trials from Axsome Therapeutics, Inc.

  • NCT02741791 A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder (STRIDE-1)
  • NCT03226522 Addressing Dementia Via Agitation-Centered Evaluation (ADVANCE)
  • NCT03595579  Assessing Symptomatic Clinical Episodes in Depression (ASCEND)
 

Clinical Trials from Azevan Pharmaceuticals

  • NCT02922166 Effects of SRX246 on an Experimental Model of Fear and Anxiety in Humans
 

Clinical Trials from The Cleveland Clinic

  • NCT03113968 ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD) (ELEKT-D)
 

Clinical Trials from Yale University

 

Clinical Trials from Weill Medical College of Cornell University

  • NCT03026127 A Novel Cognitive Reappraisal Intervention for Suicide Prevention (CRISP)
 

Clinical Trials from University of Maryland

  • NCT02067975 Tryptophan MRI in People With Schizophrenia and Healthy Controls
  • NCT02884908 Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD
 

Clinical Trials from Northwell Health

  • NCT02822092 Striatal Connectivity and Clinical Outcome in Psychosis
 

Clinical Trials from Duke University

  • NCT03069482 Feasibility Trial of a Tailored Smoking Cessation App for People With Serious Mental Illness
 

Clinical Trials from Mclean Hospital

  • NCT02188121 Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients (FITNESS)
 

Clinical Trials from Atlanta Center for Medical Research

  • NCT02932943 A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)
 

Clinical Trials from University of Nebraska

  • NCT02824627 Oxytocin on Irritability/Emotional Dysregulation of Disruptive Behavior and Mood Disorders
 
Clinical Trials from New York State Psychiatric Institute
  • NCT01931202 Mechanisms of Antidepressant Non-Response in Late-Life Depression
  • NCT03169816 Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder
  • NCT02557945 Gabapentin in Patients at Clinical Risk for Psychosis
 
Clinical Trials from University of Alabama at Birmingham
  • NCT02034253 Glutamate, Brain Connectivity and Duration of Untreated Psychosis (DUP)
 
Clinical Trials from Florida Atlantic University
  • NCT02717130 Aripiprazole, Abilify Maintena Collaborative Clinical Protocol

 Clinical Trials from Massachusetts General Hospital

  • NCT01246765 National Pregnancy Registry for Atypical Antipsychotics
  • NCT02505984 Preventing Postpartum Depression With Intranasal Oxytocin (IN-OXT)
 
 
Clinical Trials from Hartford University
  • NCT02120729 Pharmacogenetic Decision Support IT System for Psychiatric Hospitalization: RCT (CYP-GUIDES)
 
 
Clinical Trials from the NIMH
  • NCT02120729 Decision Support IT System for Psychiatric Hospitalization